Camptothecins in Cancer Therapy
26%
off

Camptothecins in Cancer Therapy

Edited by  , Edited by 

Free delivery worldwide

Available. Dispatched from the UK in 3 business days
When will my order arrive?

Description

This is a critical review of our current understanding of camptothecins, their shortcomings, and of the possibilities for improving their clinical performance. The authors discuss new camptothecin analog development, drug delivery issues for optimizing their anticancer activity, and their potential use in a variety of different cancers. Additional chapters describe what is known about the biochemistry, the pharmacology, and the chemistry of the camptothecins, including the mechanism of topoisomerase and how camptothecins poison this enzyme, the use of animal models in defining the anticancer potential of camptothecins, and the question of camptothecin resistance.show more

Product details

  • Hardback | 460 pages
  • 158 x 232 x 30mm | 961.62g
  • Humana Press Inc.
  • Totowa, NJ, United States
  • English
  • 2005 ed.
  • biography
  • 1588290271
  • 9781588290274

Review quote

"...an excellent all-around reference appropriate for researchers or clinicians in anticancer drug literature." - Doody's Health Science Book Review Journalshow more

Back cover copy

Clinical interest in the camptothecins continues to expand even though this class of topoisomerase I inhibitors has been studied for almost 50 years, and two early generation members of the family have gained FDA approval. In Camptothecins in Cancer Therapy, leading clinicians and researchers critically review our current understanding of camptothecins, their shortcomings, and the possibilities for improving their clinical performance. The authors discuss new camptothecin analog development, drug delivery issues for optimizing their anticancer activity, and their potential use in a variety of different cancers. Additional chapters describe what is known about the biochemistry, the pharmacology, and the chemistry of the camptothecins, including the mechanism of topoisomerase and how camptothecins poison this enzyme, the use of animal models in defining the anticancer potential of camptothecins, and the question of camptothecin resistance. Authoritative and up-to-date, Camptothecins in Cancer Therapy provides a comprehensive summary of camptothecin research, as well as a much-needed guide to all the latest information on their optimal therapeutic applications.show more

Table of contents

Part I: Biochemistry, Pharmacology, and Chemistry Mechanism of Action of Topoisomerase 1 Poisons Leroy F. Liu and Shyamal D. Desai Crystallographic Insight Into the Mechanism of Drug-Induced Topoisomerase I DNA Damage Alex B. Burgin, Jr., Michael D. Feese, Bart L. Staker, and Lance Stewart Inhibitors of Topoisomerase I Function Sidney M. Hecht Cytotoxic Mechanisms of the Topoisomerase 1 Inhibitors Yves G. Pommier, Juana Barcelo, Takahisa Furuta, Haruyuki Takemura, Olivier Sordet, and ZhiYong Liao Biochemical and Genetic Analyses of DNA Topoisomerase 1-Mediated DNA Damage Robert C. A. M. van Waardenburg and Mary-Ann Bjornsti Preclinical Models for Evaluating Topoisomerase I-Targeted Drugs Aarti S. Juvekar, Joyce Thompson, Clinton F. Stewart, and Peter J. Houghton Mechanisms of Resistance to Camptothecins Zeshaan A. Rasheed and Eric H. Rubin Recent Advances in Camptothecin Drug Design and Delivery Strategies Thomas G. Burke, Tian-Xiang Xiang, Bradley D. Anderson, and Lori J. Latus Part II: Clinical Perspectives Clinical Experience With 9-Aminocamptothecin: Lessons for New Drug Development Chris H. Takimoto Clinical Studies of Rubitecan (9-Nitro 20(S) Camptothecin) Hilary Hewes, Judith A. Smith, and Claire Verschraegen Irinotecan: Current Clinical Status and Pharmacological Aspects Laurent P. Rivory Clinical Experience With Topotecan Aimee K. Bence and Val R. Adams The Clinical Development of Lurtotecan: Experience With Water-Soluble and Liposomal Forms Keith T. Flaherty, James P. Stevenson, Christopher J. Twelves, and Peter J. O'Dwyer Preclinical and Clinical Development of Exatecan (DX-8951f): A Hexacyclic Camptothecin Analog Eric K. Rowinsky Camptothecins in the Treatment of Primary Brain Tumors Clinton F. Stewart,Markos Leggas, and Henry S. Friedman Camptothecins in the Treatment of Lung Cancer Pankaj Kumar, Missak Haigentz, Jr., Jorge Gomez, and Roman Perez-Soler Use of Camptothecins in the Treatment of Leukemia and Related Disorders Benjamin M. F. Mow and Scott H. Kaufmann Indexshow more